HOME >> MEDICINE >> NEWS
NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks

The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is restructuring its HIV/AIDS clinical trials networks and soliciting investigators and institutions to lead the reorganized effort. This reorganization, designed in response to both the changing face of the AIDS epidemic and evolving scientific challenges, will enable NIAID and its many collaborators to effectively continue their research for safe, effective and affordable drugs, preventive strategies and HIV vaccines. The new network leadership that will be established through this process will direct, coordinate and conduct NIAID-funded HIV/AIDS clinical research both domestically and internationally. NIAID, part of the National Institutes of Health (NIH), supports the world's largest portfolio of clinical research in HIV prevention, vaccine and treatment.

"This clinical leadership solicitation reflects our vision to improve coordination, collaboration and flexibility in NIAID-supported HIV/AIDS prevention, vaccine and treatment research," says NIAID Director Anthony S. Fauci, M.D. "The current NIAID AIDS research structure was critical to the discovery of antiretrovirals to treat HIV-1 in adults and children; the development of strategies to successfully prevent mother-to-child HIV transmission; and the significant progress in the global search for an AIDS vaccine. This newly designed clinical research structure will now provide us with the opportunity to build on those successes and address future global research challenges."

The leadership solicitation, known as a Request for Applications (RFA), is now available for review by interested parties on the NIAID Web site (see below for details). A second RFA, to be released in early 2005, will solicit applications for the Clinical Trial Units (CTUs) that will implement the research plans of the networks. Funding for the two RFAs is expected to total up to $300 million for the first year, and funding may conti
'"/>

Contact: NIAID Press Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
1-Dec-2004


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID launches influenza genome sequencing project
6. NIAID launches program to improve medical tools against emerging infectious diseases
7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... Island, SC (PRWEB) , ... February 08, 2016 , ... ... surrounding areas with a vital new community enrichment program, has teamed up with Citizens ... women and children suffering from intimate abuse. To support all those victimized by the ...
(Date:2/8/2016)... , ... February 08, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Security Executive® (ISE®) West Awards. , Awards include the Information Security ...
(Date:2/8/2016)... ... 2016 , ... Discover the Rocky Mountain region’s longest running and impressive garden ... Attendees also get to see the most incredible gardens and home improvement experts that ... the Colorado Convention Center - 700 14th St. Denver CO, is an exciting event ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, ... how healthcare companies can use newly released government data on populations and physicians ... and intervene and capture the value they create to succeed in new economic ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence ... and the most minimally invasive approaches. , Women who have had multiple vaginal ... risk factors include surgery to the pelvic floor, connective tissue disorders, and obesity. ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Velano Vascular, a medical technology company transforming ... their practitioners, announced today that the company has raised ... the proceeds from this financing, an extension of a ... to support the development and commercialization of the company,s ... Philadelphia , and a number ...
(Date:2/8/2016)... Therapeutics, Inc. announced today that the United States Patent and ... the use of NephroFlow to treat acute kidney injury (AKI). ... "We are pleased to secure our rights to such a ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are pleased ...
(Date:2/8/2016)...  Astellas Pharma Inc. President and Chief Executive Officer ... Robinson as president, Americas Operations, for Astellas US LLC, ... South America , effective April 1, 2016.  Robinson ... organization in the United States -- ... Yoshida , who is retiring in June 2016.  ...
Breaking Medicine Technology:
Cached News: